The Medicines Company to Present Data at IDWeek 2017 on Infectious Disease Portfolio Including Recently Approved Antibiotic VABOMERE™ (meropenem and vaborbactam)

28 Sep 2017

The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products will be featured in presentations at IDWeek 2017 to be held October 4-8, 2017 in San Diego. The Medicines Company’s infectious disease research and product development is focused on the most serious multi-drug resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE).

The Company will present data on VABOMERE™, its recently FDA-approved fixed-dose meropenem-vaborbactam antibiotic combination, from the TANGO-2, the multi-center, randomized, open-label Phase III clinical trial of VABOMERE versus “best available therapy” in patients with serious infections (complicated urinary tract infections (cUTI), bacteremia, hospital-acquired or ventilator-associated bacterial pneumonia, and complicated intraabdominal infections) suspected or documented to be caused by CRE.

Data from studies of the Company’s other marketed products ORBACTIV® (oritavancin) and MINOCIN® (minocycline) for Injection will also be presented.

“We are delighted to have the opportunity at IDWeek, the premier gathering of the infectious disease community, to showcase our industry leading portfolio of anti-infectives, including presentation of key data for VABOMERE which was exquisitely designed to address the growing problem of KPC-producing CRE,” said Michael Dudley, PharmD, FIDSA, Senior Vice President, Head of R&D and Co-Leader of The Medicines Company’s Infectious Disease Business.

Tony Kingsley, President and Chief Operating Officer of The Medicines Company, added, “We recognize the growing prevalence of CRE in all settings of care in the U.S. We are pleased to be able to discuss the findings from our TANGO-2 trial in multidrug resistant infections where there is presently no standard of care and outcomes are often poor.”

IDWeek is a forum for health professionals of varied backgrounds to collaborate, cooperate, and learn from each other’s expertise. With common issues and challenges cutting across our four disciplines, IDWeek provides an opportunity to learn from each other’s knowledge, experience and expertise, for the improvement of patient care and public health. Details of The Medicines Company’s presentations are provided below. The complete program of titles, abstracts, and electronic versions of posters can be accessed following their presentations on The Medicines Company website at http://www.themedicinescompany.com/investors/events or on the IDWeek 2017 website at http://www.idweek.org. All times listed below are in Pacific Daylight Time.

                 
Date   Time   Product   Event   Details
Thursday October 5th   3:03 PM   VABOMERE   New Antibiotics: What's in the Pipeline
      <p class="bwcellpmargin">
        &nbsp;
      </p>
      <p class="bwcellpmargin">
        <b>Overview of Meropenem-Vaborbactam </b>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation author</i>: M. Dudley
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <p class="bwcellpmargin">
        Symposium
      </p>
      <p class="bwcellpmargin">
        <br>
        Room 20ABCD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Friday October 6th
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      7:00 AM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        8:15 AM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <p class="bwcellpmargin">
        <b>Pipeline 2.0: </b>New Antibiotics: What's in the Pipeline
      </p>
      <p class="bwcellpmargin">
        &nbsp;
      </p>
      <p class="bwcellpmargin">
        <b>Panelists: </b>M. Dudley, The Medicines Company; S. Cammarata, 
        Melinta Therapeutics; E. Ellis-Grosse, Zavante Therapeutics; , R. 
        Echols, ID3C; I. Friedland, Friedland Strategic Consulting; P 
        .McGovern, Paratek Pharmaceuticals; Steven P. Gelone, Nabriva 
        Therapeutics AG; David Huang, Motif BioSciences; Amanda Paschke, 
        Merck &amp; Co., Inc.; P. Horn, Tetraphase Pharmaceuticals
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <p class="bwcellpmargin">
        Panel Discussion and Q&amp;A
      </p>
      <p class="bwcellpmargin">
        <br>
        Room
      </p>
      <p class="bwcellpmargin">
        <br>
        06DE
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Friday October 6th
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      <p class="bwcellpmargin">
        12:30 PM
      </p>
      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session</i>: Expanded Spectrum - New

      <p class="bwcellpmargin">
        Antimicrobial Susceptibility Testing
      </p>
      <p class="bwcellpmargin">
        <b>Activity of Meropenem-Vaborbactam Against Enterobacteriaceae 
        Isolates Carrying <i>bla</i></b><sub><b>KPC</b></sub><b> Collected 
        Worldwide </b>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors</i>: M. Castanheira, R.E. Mendes, L.R. 
        Duncan, L.N. Woosley, R.K. Flamm
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <p class="bwcellpmargin">
        Poster 1234
      </p>
      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Saturday October 7th
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:30 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session: </i>Clinical Study with New Antibiotics and Antifungals

      <p class="bwcellpmargin">
        <i><b>Meropenem-Vaborbactam vs. Piperacillin-Tazobactam in TANGO I 
        (a Phase 3 Randomized, Double-blind Trial): Outcomes by Baseline 
        MIC in Adults with Complicated Urinary Tract Infections or Acute 
        Pyelonephritis </b></i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors</i>: T. Walsh, T. Bhowmick, R. Darouiche, 
        V. Zaitsev, E. Giamarellos-Bourboulis, A. Shorr, E. Fedosiuk, T. 
        File Jr., J. Loutit, O. Lomovskaya, M. Dudley, D. Perlin
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <p class="bwcellpmargin">
        Poster 1866
      </p>
      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Saturday October 7th
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:30 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session</i>: Clinical Study with New Antibiotics and Antifungals

      <p class="bwcellpmargin">
        <i><b>Meropenem-Vaborbactam vs. Best Available Therapy for 
        Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: 
        Primary Outcomes by Site of Infection </b></i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors:</i> R. Wunderink, E. 
        Giamarellos-Bourboulis, G. Rahav, A. Mathers, M. Bassetti, J. 
        Solomkin, E. Alexander, J. Loutit, S. Zhang, M. Dudley, K. Kaye
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <p class="bwcellpmargin">
        Poster 1867
      </p>
      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Saturday October 7th
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:30 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session</i>: Clinical Study with New Antibiotics and Antifungals

      <p class="bwcellpmargin">
        <i><b>Clinical Outcomes of Serious Infections due to 
        Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 
        3, Randomized, Multi-National, Open-Label Trial of 
        Meropenem-Vaborbactam (M-V) Versus Best Available Therapy (BAT)</b></i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors</i>: K. Kaye, J. Vazquez, A. Mathers, G. 
        Daikos, E. Alexander, J. Loutit, S. Zhang, M. Dudley, O. Cornely
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Poster 1862

      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Saturday

      <p class="bwcellpmargin">
        October 7th
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:30 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session:</i> Clinical Study with New Antibiotics and Antifungals

      <p class="bwcellpmargin">
        <i><b>Assessment of MIC Increases with Meropenem-Vaborbactam and 
        Ceftazidime-Avibactam in TANGOII (a Phase 3 Study of the Treatment 
        of CRE Infections) </b></i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors</i>: O. Lomovskaya, M. Castanheira, J. 
        Vazquez, K. Kaye, K. Nelson, D. Sun, E. Alexander, M. Dudley, M. 
        Yin
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Poster 1874

      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Saturday

      <p class="bwcellpmargin">
        October 7th
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:30 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session</i>: Clinical Study with New Antibiotics and Antifungals

      <p class="bwcellpmargin">
        <i><b>Meropenem-Vaborbactam: Outcomes in Subjects with Renal 
        Impairment in Phase 3 Studies TANGO I and II</b></i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors</i>: A. Mathers, W. Hope, K. Kaye, J. 
        Loutit, E. Alexander, M. Dudley, J. Vazquez
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Poster 1879

      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Saturday

      <p class="bwcellpmargin">
        October 7th
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:30 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session: </i>Clinical Study with New Antibiotics and Antifungals

      <p class="bwcellpmargin">
        <i><b>Meropenem-Vaborbactam Pharmacokinetics in Subjects with 
        Chronic Renal Impairment, Including Hemodialysis</b></i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors:</i> C. Rubino, D. Griffith, S. Bhavnani, 
        J. Loutit, B. Lohse, M. Dudley, P. Ambrose
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Poster 1835

      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Saturday

      <p class="bwcellpmargin">
        October 7th
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:00 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:30 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session:</i> Clinical Study with New Antibiotics and Antifungals

      <p class="bwcellpmargin">
        <i><b>Meropenem-Vaborbactam vs. Best Available Therapy for 
        Carbapenem-Resistant Enterobacteriaceae Infections in TANGO 
        II:Outcomes in Immunocompromised Patients</b></i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors:</i> D. Paterson, E. J. Kwak, T. Bhowmick, 
        E. Alexander, J. Loutit, S. Zhang, M. Dudley, T. Walsh
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Poster 1868

      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Saturday

      <p class="bwcellpmargin">
        October 7th
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:00 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:30 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      VABOMERE
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session:</i> Clinical Study with New Antibiotics and Antifungals

      <p class="bwcellpmargin">
        <i><b>Meropenem-Vaborbactam Pharmacokinetic-Pharmacodynamic 
        (PK-PD) Target Attainment Analyses as Support for Dose Selection 
        in Patients with Normal Renal Function and Varying Degrees of 
        Renal Impairment</b></i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors:</i> S. Bhavnani, M. Trang, D. Griffith, 
        O. Lomovskaya, J. Hammel, J. Loutit, M. Dudley, P. Ambrose, C. 
        Rubino
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Poster 1852

      <p class="bwcellpmargin">
        <br>
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Thursday October 5th
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:30 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      MINOCIN
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session: </i>Use of PK/PD to optimize existing antibiotics and 
      antifungal

      <p class="bwcellpmargin">
        <b>Pharmacokinetics and Tissue Distribution of Minocycline 
        following Intravenous Administration in Rabbits</b><i> </i>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors</i>: V. Petraitis, R. Petraitiene, B. W. 
        Maung, T. Nolan, D. Griffith, M. Dudley, T. Walsh
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Poster 804

      <p class="bwcellpmargin">
        &nbsp;
      </p>
      <p class="bwcellpmargin">
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Friday October 6th
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom">
      12:30 PM

      <p class="bwcellpmargin">
        to
      </p>
      <p class="bwcellpmargin">
        2:00 PM
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      ORBACTIV
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      <i>Session</i>: Expanded Spectrum - New

      <p class="bwcellpmargin">
        Antimicrobial Susceptibility Testing
      </p>
      <p class="bwcellpmargin">
        <b>Analysis of Oritavancin Activity against </b>
      </p>
      <p class="bwcellpmargin">
        <b>Gram-Positive Clinical Isolates Responsible for Bacterial 
        Endocarditis in United States and European Hospitals (2008-2016)</b>
      </p>
      <p class="bwcellpmargin">
        <i>Presentation authors</i>: M.A. Pfaller, H.S. Sader, D. 
        Shortridge, R.K. Flamm, R.E. Mendes
      </p>
    </td>
    <td class="bwsinglebottom">
      &nbsp;
    </td>
    <td class="bwpadl0  bwvertalignt bwalignl bwsinglebottom">
      Poster 864

      <p class="bwcellpmargin">
        &nbsp;
      </p>
      <p class="bwcellpmargin">
        Hall CD
      </p>
    </td>
  </tr>
  <tr>
    <td>
    </td>
    <td>
      &nbsp;
    </td>
    <td>
    </td>
    <td>
      &nbsp;
    </td>
    <td>
    </td>
    <td>
      &nbsp;
    </td>
    <td>
    </td>
    <td>
      &nbsp;
    </td>
    <td>
    </td>
  </tr>
</tbody></table>
<p>
  <b>About VABOMERE</b>™
</p>
<p>
  VABOMERE™ (meropenem and vaborbactam) is indicated for the treatment of 
  patients 18 years of age and older with complicated urinary tract 
  infections (cUTI) including pyelonephritis caused by the following 
  susceptible microorganisms: <i>Escherichia coli</i>, <i>Klebsiella 
  pneumoniae</i>, and <i>Enterobacter cloacae species</i> complex.
</p>
<p>
  To reduce the development of drug-resistant bacteria and maintain the 
  effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should 
  be used only to treat or prevent infections that are proven or strongly 
  suspected to be caused by susceptible bacteria.
</p>
<p>
  <b>IMPORTANT SAFETY INFORMATION</b>
</p>
<p>
  <b>Contraindications</b>
</p>
<p>
  VABOMERE is contraindicated in patients with known hypersensitivity to 
  any components of VABOMERE (meropenem and vaborbactam), or to other 
  drugs in the same class or in patients who have demonstrated 
  anaphylactic reactions to beta-lactam antibacterial drugs.
</p>
<p>
  <b>Warnings and Precautions</b>
</p>
<ul>
  <li class="bwlistitemmargb">
    Hypersensitivity reactions were reported in patients treated with 
    VABOMERE in the clinical trials. Serious and occasionally fatal 
    hypersensitivity (anaphylactic) reactions and serious skin reactions 
    have been reported in patients receiving therapy with beta-lactam 
    antibacterial drugs. There have been reports of individuals with a 
    history of penicillin hypersensitivity who have experienced severe 
    hypersensitivity reactions when treated with another beta-lactam 
    antibacterial drug. If an allergic reaction to VABOMERE occurs, 
    discontinue the drug immediately.
  </li>
  <li class="bwlistitemmargb">
    Seizures and other adverse Central Nervous System (CNS) experiences 
    have been reported during treatment with meropenem, which is a 
    component of VABOMERE. Close adherence to the recommended dosage 
    regimens is urged, especially in patients with known factors that 
    predispose to convulsive activity.
  </li>
  <li class="bwlistitemmargb">
    <i>Clostridium difficile</i>-associated diarrhea (CDAD) has been 
    reported with use of nearly all antibacterial agents, including 
    VABOMERE, and may range in severity from mild diarrhea to fatal 
    colitis. Careful medical history is necessary since CDAD has been 
    reported to occur over two months after the administration of 
    antibacterial agents. If CDAD is suspected or confirmed, ongoing 
    antibacterial drug use not directed against <i>C. difficile</i> may 
    need to be discontinued.
  </li>
  <li class="bwlistitemmargb">
    The concomitant use of VABOMERE and valproic acid or divalproex sodium 
    is generally not recommended. Case reports in the literature have 
    shown that co-administration of carbapenems, including meropenem, to 
    patients receiving valproic acid or divalproex sodium results in a 
    reduction in valproic acid concentrations. The valproic acid 
    concentrations may drop below the therapeutic range as a result of 
    this interaction, therefore increasing the risk of breakthrough 
    seizures. If administration of VABOMERE is necessary, consider 
    supplemental anticonvulsant therapy.
  </li>
  <li class="bwlistitemmargb">
    In patients with renal impairment, thrombocytopenia has been observed 
    in patients treated with meropenem, but no clinical bleeding has been 
    reported.
  </li>
  <li class="bwlistitemmargb">
    Alert patients receiving VABOMERE on an outpatient basis regarding 
    adverse reactions such as seizures, delirium, headaches and/or 
    paresthesias that could interfere with mental alertness and/or cause 
    motor impairment.
  </li>
  <li class="bwlistitemmargb">
    Prescribing VABOMERE in the absence of a proven or strongly suspected 
    bacterial infection is unlikely to provide benefit to the patient and 
    increases the risk of drug-resistant bacteria.
  </li>
  <li class="bwlistitemmargb">
    As with other antibacterial drugs, prolonged use of VABOMERE may 
    result in overgrowth of nonsusceptible organisms.
  </li>
</ul>
<p>
  <b>Adverse Reactions </b><br>The most frequently reported adverse 
  reactions occurring in ?3% of patients treated with VABOMERE were 
  headache, phlebitis/infusion site reactions, and diarrhea.
</p>
<p>
  <b>About MINOCIN® (minocycline) for Injection</b>
</p>
<p>
  MINOCIN® (minocycline) for Injection is indicated for the treatment of 
  infections due to susceptible strains of designated microorganisms, 
  including <i>Acinetobacter</i> species bacteria. For additional 
  indications and designated susceptible pathogens, please see the full 
  prescribing information available at <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.minociniv.com&amp;esheet=51691561&amp;newsitemid=20170928006296&amp;lan=en-US&amp;anchor=www.MINOCINiv.com&amp;index=4&amp;md5=a30f692fa13ede870e9f8391c2c5e070" rel="nofollow">www.MINOCINiv.com</a>.
</p>
<p>
  <b>Important Safety Information </b><br><b>Contraindications</b>
</p>
<p>
  MINOCIN® for Injection is contraindicated in persons who have shown 
  hypersensitivity to any of the tetracyclines or to any of the components 
  of the product formulation.
</p>
<p>
  <b>Warnings and Precautions </b><br><i>Tooth Development</i>
</p>
<p>
  MINOCIN® for Injection, like other tetracycline-class antibacterials, 
  can cause fetal harm when administered to a pregnant woman. If any 
  tetracycline is used during pregnancy, or if the patient becomes 
  pregnant while taking these drugs, the patient should be apprised of the 
  potential hazard to the fetus. The use of drugs of the tetracycline 
  class during tooth development (last half of pregnancy, infancy, and 
  childhood to the age of 8 years) may cause permanent discoloration of 
  the teeth (yellow-gray-brown).
</p>
<p>
  This adverse reaction is more common during long-term use of the drugs 
  but has been observed following repeated short-term courses. Enamel 
  hypoplasia has also been reported. Tetracycline drugs, therefore, should 
  not be used during tooth development unless other drugs are not likely 
  to be effective or are contraindicated.
</p>
<p>
  <i>Skeletal Development </i><br>All tetracyclines form a stable 
  calcium complex in any bone-forming tissue. A decrease in the fibula 
  growth rate has been observed in premature human infants given oral 
  tetracycline in doses of 25 mg/kg every six hours. This reaction was 
  shown to be reversible when the drug was discontinued.
</p>
<p>
  Results of animal studies indicate that tetracyclines cross the 
  placenta, are found in fetal tissues, and can have toxic effects on the 
  developing fetus (often related to retardation of skeletal development). 
  Evidence of embryotoxicity has been noted in animals treated early in 
  pregnancy.
</p>
<p>
  <i>Dermatologic Reaction </i><br>Drug Rash with Eosinophilia and 
  Systemic Symptoms (DRESS) including fatal cases have been reported with 
  minocycline use. If this syndrome is recognized, the drug should be 
  discontinued immediately.
</p>
<p>
  <i>Anti-anabolic Action </i><br>The anti-anabolic action of the 
  tetracyclines may cause an increase in BUN. While this is not a problem 
  in those with normal renal function, in patients with significantly 
  impaired function, higher serum levels of tetracycline may lead to 
  azotemia, hyperphosphatemia, and acidosis. Under such conditions, 
  monitoring of creatinine and BUN is recommended, and the total daily 
  dosage should not exceed 200 mg in 24 hours. If renal impairment exists, 
  even usual oral or parenteral doses may lead to systemic accumulation of 
  the drug and possible liver toxicity.
</p>
<p>
  <i>Photosensitivity </i><br>Photosensitivity manifested by an 
  exaggerated sunburn reaction has been observed in some individuals 
  taking tetracyclines. This has been reported with minocycline.
</p>
<p>
  <i>Central Nervous System Effects </i><br>Central nervous system side 
  effects including light-headedness, dizziness or vertigo have been 
  reported. Patients who experience these symptoms should be cautioned 
  about driving vehicles or using hazardous machinery while on minocycline 
  therapy. These symptoms may disappear during therapy and usually 
  disappear rapidly when the drug is discontinued.
</p>
<p>
  <i>Clostridium difficile Associated Diarrhea </i><br>Clostridium 
  difficile associated diarrhea (CDAD) has been reported with use of 
  nearly all antibacterial agents, including MINOCIN® for Injection, and 
  may range in severity from mild diarrhea to fatal colitis. If CDAD is 
  suspected or confirmed, ongoing antibacterial use not directed against 
  C. difficile may need to be discontinued.
</p>
<p>
  <i>Intracranial Hypertension </i><br>Intracranial hypertension (IH, 
  pseudotumor cerebri) has been associated with the use of tetracyclines 
  including MINOCIN® for Injection. Clinical manifestations of IH include 
  headache, blurred vision, diplopia, and vision loss; papilledema can be 
  found on fundoscopy. Women of childbearing age who are overweight or 
  have a history of IH are at greater risk for developing tetracycline 
  associated IH. Concomitant use of isotretinoin and MINOCIN® for 
  Injection should be avoided because isotretinoin is also known to cause 
  pseudotumor cerebri.
</p>
<p>
  Although IH typically resolves after discontinuation of treatment, the 
  possibility for permanent visual loss exists. If visual disturbance 
  occurs during treatment, prompt ophthalmologic evaluation is warranted. 
  Since intracranial pressure can remain elevated for weeks after drug 
  cessation patients should be monitored until they stabilize.
</p>
<p>
  As with other antibacterial preparations, use of this drug may result in 
  overgrowth of nonsusceptible organisms, including fungi. If 
  superinfection occurs, the antibacterial should be discontinued and 
  appropriate therapy instituted.
</p>
<p>
  Hepatotoxicity has been reported with minocycline; therefore, 
  minocycline should be used with caution in patients with hepatic 
  dysfunction and in conjunction with other hepatotoxic drugs.
</p>
<p>
  Incision and drainage or other surgical procedures should be performed 
  in conjunction with antibiotic antibacterial therapy when indicated.
</p>
<p>
  MINOCIN® for Injection contains magnesium sulfate heptahydrate. Because 
  magnesium is excreted primarily by the kidney, serum levels of magnesium 
  should be monitored in patients with renal impairment.
</p>
<p>
  Because MINOCIN® for Injection contains magnesium, close monitoring is 
  recommended in patients with heart block or myocardial damage.
</p>
<p>
  Prescribing MINOCIN® for Injection in the absence of a proven or 
  strongly suspected bacterial infection or a prophylactic indication is 
  unlikely to provide benefit to the patient and increases the risk of the 
  development of drug-resistant bacteria.
</p>
<p>
  <b>Adverse Reactions</b>
</p>
<p>
  For a complete list of adverse reactions that have been observed in 
  patients receiving tetracyclines, consult the full US prescribing 
  information for MINOCIN® for Injection.
</p>
<p>
  Please see <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.minociniv.com%2F&amp;esheet=51691561&amp;newsitemid=20170928006296&amp;lan=en-US&amp;anchor=www.MINOCINiv.com&amp;index=5&amp;md5=5fb27f8fb1c4121e31213b6eee64b72d" rel="nofollow">www.MINOCINiv.com</a> 
  for the full prescribing information.
</p>
<p>
  <b>About ORBACTIV® (oritavancin) for Injection</b>
</p>
<p>
  ORBACTIV® (oritavancin) for Injection is indicated for the treatment of 
  adult patients with acute bacterial skin and skin structure infections 
  (ABSSSI) caused or suspected to be caused by susceptible isolates of the 
  following gram-positive microorganisms: Staphylococcus aureus (including 
  methicillin-susceptible [MSSA] and methicillin–resistant [MRSA] 
  isolates), Streptococcus pyogenes, Streptococcus agalactiae, 
  Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. 
  anginosus, S. intermedius, and S. constellatus), and Enterococcus 
  faecalis (vancomycin-susceptible isolates only).
</p>
<p>
  <b>Important Safety Information</b>
</p>
<p>
  <b>Contraindications</b>
</p>
<p>
  Use of intravenous unfractionated heparin sodium is contraindicated for 
  120 hours (5 days) after ORBACTIV® administration because the activated 
  partial thromboplastin time (aPTT) test results are expected to remain 
  falsely elevated for approximately 120 hours (5 days) after ORBACTIV® 
  administration.
</p>
<p>
  ORBACTIV® is contraindicated in patients with known hypersensitivity to 
  ORBACTIV®.
</p>
<p>
  <b>Warnings and Precautions</b>
</p>
<p>
  <i>Coagulation test interference:</i> ORBACTIV® has been shown to 
  artificially prolong aPTT for up to 120 hours, and may prolong PT and 
  INR for up to 12 hours, ACT for up to 24 hours, and D-dimer for up to 72 
  hours.
</p>
<p>
  Hypersensitivity reactions have been reported with the use of 
  antibacterial agents including ORBACTIV®. Discontinue infusion if signs 
  of acute hypersensitivity occur. Monitor closely patients with known 
  hypersensitivity to glycopeptides.
</p>
<p>
  Infusion-related reactions have been reported. Slow the rate or 
  interrupt infusion if infusion reaction develops.
</p>
<p>
  <i>Clostridium difficile-associated colitis:</i> Evaluate patients if 
  diarrhea occurs.
</p>
<p>
  <i>Concomitant warfarin use:</i> Patients should be monitored for 
  bleeding if concomitantly receiving ORBACTIV® and warfarin.
</p>
<p>
  <i>Osteomyelitis:</i> Institute appropriate alternate antibacterial 
  therapy in patients with confirmed or suspected osteomyelitis.
</p>
<p>
  Prescribing ORBACTIV® in the absence of a proven or strongly suspected 
  bacterial infection is unlikely to provide benefit to the patient and 
  increases the risk of the development of drug-resistant bacteria.
</p>
<p>
  <b>Adverse Reactions</b>
</p>
<p>
  The most common adverse reactions (? 3%) in patients treated with 
  ORBACTIV® were headache, nausea, vomiting, limb and subcutaneous 
  abscesses, and diarrhea.
</p>
<p>
  Please see <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.orbactiv.com&amp;esheet=51691561&amp;newsitemid=20170928006296&amp;lan=en-US&amp;anchor=www.ORBACTIV.com&amp;index=6&amp;md5=2565913244190c805ea862884cacd859" rel="nofollow">www.ORBACTIV.com</a> 
  for the full prescribing information.
</p>
<p>
  <b>About The Infectious Disease Business</b>
</p>
<p>
  The Medicines Company Infectious Disease Business (MDCO IDC) is 
  committed to bringing life-saving antimicrobial products to patients 
  with the most serious drug-resistant infections – infections caused by 
  “super bugs” which are no longer treatable with available antibiotics. 
  MDCO IDC encompasses basic research and drug discovery focused on 
  bacterial mechanisms of drug resistance; drug development focused on the 
  most threatening bacterial diseases; and a distribution and commercial 
  infrastructure that serves the leading hospitals and healthcare 
  facilities in the United States. MDCO IDC recently received approval for 
  VABOMERE to treat serious gram-negative infections, such as complicated 
  urinary tract infections, including those infections caused by bacteria 
  resistant to currently available carbapenems. MDCO IDC has a leading 
  pipeline of novel agents directed towards existing and emerging 
  multidrug-resistant bacteria.
</p>
<p>
  In addition to the development and approval of VABOMERE, MDCO IDC has, 
  since 2014, successfully developed and launched two antibiotics against 
  serious infections: ORBACTIV<sup>® </sup>(oritavancin) for the treatment 
  of acute bacterial skin and skin-structure infections in adults, caused 
  by designated pathogens, including methicillin-resistant Staphylococcus 
  aureus, and a new formulation of MINOCIN<sup>®</sup> (minocycline) for 
  Injection, which is among the few FDA-approved agents for the treatment 
  of infections due to <i>Acinetobacter spp., </i>a pathogen classified by 
  the CDC to be a serious antimicrobial resistance threat. For more 
  information on these products, including their respective important 
  safety information and package inserts, please see <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.orbactiv.com%2F&amp;esheet=51691561&amp;newsitemid=20170928006296&amp;lan=en-US&amp;anchor=www.ORBACTIV.com&amp;index=7&amp;md5=c8d60aeda57207568963fe9962e75c2b" rel="nofollow">www.ORBACTIV.com</a> 
  and <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.minociniv.com%2F&amp;esheet=51691561&amp;newsitemid=20170928006296&amp;lan=en-US&amp;anchor=www.MINOCINiv.com&amp;index=8&amp;md5=83394cca72c9ade789adc942ae54229a" rel="nofollow">www.MINOCINiv.com</a>.
</p>
<p>
  <b>About BARDA</b>
</p>
<p>
  In February 2014, The Medicines Company Infectious Disease Business was 
  awarded a cost-sharing contract by the Biomedical Advanced Research and 
  Development Authority (BARDA), a division of the Office of the Assistant 
  Secretary for Preparedness and Response within the U.S. Department of 
  Health and Human Services (HHS), of which $55.8 million in federal funds 
  have been obligated to date to support the development of VABOMERE.
</p>
<p>
  In September 2016, The Medicines Company entered into a new strategic 
  partnership with BARDA that will provide the Company with the potential 
  for up to $132 million to support the development of new antibiotics to 
  fight drug-resistant, gram-negative infections (HHSO100201600026C). The 
  partnership was established under HHS’s Other Transactional Authority 
  (OTA), and is a distinctive, flexible, portfolio-based approach to 
  funding drug development. The Medicines Company was awarded $32 million 
  in initial funding, and up to an additional $100 million (pending the 
  availability of funding) over approximately five years, if all options 
  to extend the partnership are exercised by BARDA and The Medicines 
  Company. The initial $32 million award supports further development of 
  VABOMERE as well as advancement of the Company’s early stage pipeline. 
  Funding provided under any subsequent options exercised by BARDA and The 
  Medicines Company, will also support the advancement of antibiotics in 
  MDCO IDC’s portfolio of new antibiotic drug candidates targeting drug 
  resistant bacteria.
</p>
<p>
  <b>About The Medicines Company</b>
</p>
<p>
  The Medicines Company is a biopharmaceutical company driven by an 
  overriding purpose – to save lives, alleviate suffering and contribute 
  to the economics of healthcare. The Company’s mission is to create 
  transformational solutions to address the most pressing healthcare needs 
  facing patients, physicians and providers in serious infectious disease 
  care and cardiovascular care. The Company is headquartered in 
  Parsippany, New Jersey, with a global innovation center in California.
</p>
<p>
  <b>Forward-Looking Statements</b>
</p>
<p>
  Statements contained in this press release that are not purely 
  historical may be deemed to be forward-looking statements for purposes 
  of the safe harbor provisions under The Private Securities Litigation 
  Reform Act of 1995. Without limiting the foregoing, the words 
  "believes," "anticipates," "expects," “potential,” and similar 
  expressions are intended to identify forward-looking statements. These 
  forward-looking statements involve known and unknown risks and 
  uncertainties that may cause the Company's actual results, levels of 
  activity, performance or achievements to be materially different from 
  those expressed or implied by these forward-looking statements. 
  Important factors that may cause or contribute to such differences 
  include whether clinical trials will advance on a timely basis, or at 
  all, or succeed in achieving their specified endpoints; whether 
  physicians, patients and other key decision makers will accept clinical 
  trial results; whether the Company will make regulatory submissions on a 
  timely basis, or at all; whether the Company’s regulatory submissions 
  will receive approvals from regulatory agencies on a timely basis, or at 
  all; and such other factors as are set forth in the risk factors 
  detailed from time to time in the Company's periodic reports and 
  registration statements filed with the Securities and Exchange 
  Commission, including, without limitation, the risk factors detailed in 
  the Company's Annual Report on Form 10-K filed with the Securities and 
  Exchange Commission on August 9, 2017, which are incorporated herein by 
  reference. The Company specifically disclaims any obligation to update 
  these forward-looking statements.
</p>
<p>
</p>


Contacts

The Medicines Company
Media
Meg Langan, (973) 290-6319
Vice President
margaret.langan@themedco.com
or
Investors
Krishna Gorti, M.D., (973) 290-6122
Vice President, Investor Relations
krishna.gorti@themedco.com

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com